Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2745718 | 0.98 | LMNA (0.43) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL9366512 | 0.80 | MEN1 (0.51) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL6794293 | 0.80 | MEN1 (0.51) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL6794288 | 0.76 | MEN1 (0.51) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL2612622 | 0.73 | ALDH1A1 (0.57) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL9730018 | 0.73 | MEN1 (0.53) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL9730026 | 0.73 | MEN1 (0.53) | LMNACYP2C9MEN1KMT2AL3MBTL1 | |
| SCHEMBL7397644 | 0.73 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL7433665 | 0.73 | CYP2D6 (0.45) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7433662 | 0.73 | CYP2D6 (0.45) | LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178672-B2 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase | ARQULE, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2258704-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ArQule, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | ARQULE, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111985-A1 | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase | MAPK1, MAPK14, MAPK15 | LMNA 4548/4885CYP2C9 1885/4885MEN1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.